Feedback2009 Guideline Development Group:
All members of the group completed a Declaration for the Conflict of Interest; there were no conflicts declared.
2016 Guideline Development Group:
The following members declared no interests: Si Thu Aung; Frank Bonsu; Jeremiah Chakaya; Lucy Chesire; Daniela Cirillo; Poonam Dhavan; Kathy Fiekert; Andrei Mariandyshev; Nguyen Viet Nhung; Ejaz Qadeer; Abdul Hamid Salim; Holger Schünemann; Pedro Suarez; Justin Wong Yun Yaw.
The following GDG members declared interests that were judged not to be in conflict with the policy of WHO, or the objectives of the meeting:
Kelly Dooley declared that she did not receive any salary support from drug companies for her work in the following roles and activities: Co-chair of the AIDS Clinical Trials Group (ACTG) study assessing bedaquiline and delamanid for MDR-TB; principal investigator, assessing pretomanid for tuberculosis trial, assessing pretomanid (PA-824, investigational drug) for treatment of drug-sensitive TB; investigator on trials assessing rifapentine for pregnant women with latent TB infection, rifapentine for treatment shortening in patients with pulmonary TB, high-dose rifampicin and levofloxacin for pediatric TB meningitis, high-dose isoniazid for MDR-TB, and delamanid for MDR-TB in children with and without HIV.
Mike Frick declared that his organization received noncommercial support 1) to track investment made in TB research and development; 2) to host a symposium at the Union meeting; 3) to advocate for increased funding for TB research and development, research and access to evidence-based interventions; and 4) for the management of the community research advisors’ group. Simon Schaaf declared receiving grants for pharmacokinetic drug studies in children of second-line drugs and for studying preventive therapy in MDR-TB. Carrie Tudor declared that her organization receives funding from Eli Lilly Foundation for activities related to TB and MDR-TB projects.
2021 Guideline Development Group:
Twenty-five individuals from various areas of expertise were invited to attend. All the experts completed and submitted their Declaration of Interest (DOI) and Confidentiality Undertaking forms between March – April 2021. On review of the completed DOIs, the following 8 experts declared interests that required further consideration and discussion with WHO Office of Compliance, Risk Management and Ethics (CRE): Susan ABDEL RAHMAN; Grania BRIGDEN; Daniela CIRILLO; Charles DALEY; Geraint DAVIES; Anneke HESSELING; Laia RUIZ MINGOTE; Carrie TUDOR.
Following thorough assessment and review in collaboration with the CRE no competing interests were identified with the scope of the work being undertaken by the GDG. The note for the record with details of the assessment was filed.